Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted
 schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive
 high grade glioma.
Inclusion Criteria:

 -  Patient age >18 years old

 -  Histopathological diagnosis of high grade glioma (anaplastic astrocytoma or anaplastic
 oligodendroglioma or anaplastic oligoastrocytoma or glioblastoma multiforme)

 -  Progression after standard dose (D1-5/28 days)temozolomide either during recurrence or
 adjuvant treatment approved in Magnetic Resonance imaging

 -  Karnofsky Performance Status scale >/=50 (due to brain pathology)

 -  Adequate hematological, renal and hepatic function

 -  Patients willing to participate in the study and signing the informed consent

 Exclusion Criteria:

 -  Karnofsky Performance Status scale <50

 -  Female patients with pregnancy or with suspicion of pregnancy. Patients with fertility
 will be warned for appropriate contraception during the study

 -  Patients not suitable for follow-up